References
- Heinemann L, Home PD, Hompesch M. Biosimilar insulins: guidance for data interpretation by clinicians and users. Diabetes Obes Metab. 2015;17(10):911–918.
- Pasina L, Casadei G, Nobili A. Biological agents and biosimilars: essential information for the internist. Eur J Intern Med. 2016;33:28–35.
- Beran D, Ewen M, Laing R. Constraints and challenges in access to insulin: a global perspective. Lancet Diabetes Endocrinol. 2016;4(3):275–285.
- Cefalu WT, Buse JB, Tuomilehto J, et al. Update and next steps for real-world translation of interventions for type 2 diabetes prevention: reflections from a diabetes care editors’ expert forum. Diabetes Care. 2016;39(7):1186–1201.
- Tan X, Hu J. Combination therapy for type 2 diabetes: dapagliflozin plus metformin. Expert Opin Pharmacother. 2016;17(1):117–126.
- Coiffier B. Pharmacokinetics, efficacy and safety of the rituximab biosimilar CT-P10. Expert Rev Clin Pharmacol. 2017;10(9):923–933.
- Davies M, Dahl D, Heise T, et al. Introduction of biosimilar insulins in Europe. Diabet Med. 2017;34(10):1340–1353.
- Garg SK, Wernicke-Panten K, Rojeski M, et al. Efficacy and safety of biosimilar SAR342434 insulin lispro in adults with type 1 diabetes also using insulin glargine-SORELLA 1 study. Diabetes Technol Ther. 2017;19(9):516–526.
- Home P, Derwahl KM, Ziemen M, et al. Anti-insulin antibodies and adverse events with biosimilar insulin lispro compared with Humalog insulin lispro in people with diabetes. Diabetes Technol Ther. 2018;20(2):160–170.
- Lavalle-González FJ, Khatami H. The biosimilar insulin landscape: current developments. Postgrad Med. 2014;126(6):81–92.
- Kapitza C, Nowotny I, Lehmann A, et al. Similar pharmacokinetics and pharmacodynamics of rapid-acting insulin lispro products SAR342434 and US-and EU-approved Humalog in subjects with type 1 diabetes. Diabetes Obes Metab. 2017;19(5):622–627.
- Derwahl KM, Bailey TS, Wernicke-Panten K, et al. Efficacy and safety of biosimilar SAR342434 insulin lispro in adults with type 2 diabetes, also using insulin glargine: SORELLA 2 Study. Diabetes Technol Ther. 2018;20(1):49–58.
- Thrasher J, Surks H, Nowotny I, et al. Safety of iInsulin lispro and a biosimilar insulin lispro when administered through an insulin pump. J Diabetes Sci Technol. 2018;12(3):680–686.
- National Institute for Health and Care Excellence. Type 1 diabetes in adults: diagnosis and management; 2016. [cited 2018 Aug 9]. Available from: http://www.nice.org.uk/
- National Institute for Health and Care Excellence. Type 2 diabetes in adults: management; 2017. [cited 2018 Aug 9]. Available from: http://www.nice.org.uk/
- Chiang JL, Kirkman MS, Laffel LMB, et al. Type 1 diabetes through the life span: a position statement of the American Diabetes Association. Diabetes Care. 2014;37:2034–2054.
- Edelman S, Pettus J. Challenges associated with insulin therapy in type 2 diabetes mellitus. Am J Med. 2014;127(10 Suppl):S11–6.
- Farfan-Portet MI, Gerkens S, Lepage-Nefkens I, et al. Are biosimilars the next tool to guarantee cost-containment for pharmaceutical expenditures? Eur J Health Econ. 2014;15(3):223–228.
- Edelman S, Polonsky WH, Parkin CG. Biosimilar insulins are coming: what they are, what you need to know. Curr Med Res Opin. 2014;30(11):2217–2222.
- Mielke J, Jilma B, Jones B, et al. An update on the clinical evidence that supports biosimilar approvals in Europe. Br J Clin Pharmacol. 2018;84:1415–1431.
- Halim LA, Brinks V, Jiskoot W, et al. Quality and batch-to-batch consistency of original and biosimilarepoetin products. J Pharm Sci. 2016;105(2):542–550.
- A L P, R D P, J S Z, et al. Biosimilars and new insulin versions. Endocrine Practice. 2015;21(12):1387–1394.
- Ingrasciotta Y, Cutroneo PM, Marcianò I, et al. Safety of biologics, including biosimilars: perspectives on current status and future direction. Drug Saf. 2018;41:1013–1022.